Document Detail


Evaluation of the ASPIRANT trial Evaluation of Vàclavìk J, Sedlàk R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT). A randomized, double-blind, placebo-controlled trial. Hypertension 2011;29:600-609.
MedLine Citation:
PMID:  23121615     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Several pathophysiological, clinical, and therapeutic features of resistant hypertension are far from being clearly defined. This is the case also for the efficacy of aldosterone receptor antagonists as an add-on treatment of resistant hypertension. The Addition of Spironolactone in Patients with Resistant Arterial Hypertension (ASPIRANT) trial evaluated, with a double-blind, placebo-controlled design, the effects of low-dose (25 mg/day) spironolactone as compared with placebo on clinic and ambulatory blood pressure in 117 resistant hypertensive obese patients, already under treatment with at least four antihypertensive drugs. The primary study endpoint was the achievement of a statistically significant difference in the systo-diastolic blood pressure reduction during the daytime period between the spironolactone-treated and the placebo-treated group. The results show that aldosterone blockade was associated with a significant reduction in clinic, 24-h and daytime systolic (but not in diastolic) blood pressure as compared with the placebo-treated group, the systo-diastolic blood pressure difference between the two treatment regimens amounting to 5.4/1.0 mmHg. Although a number of limitations weaken some of the study conclusions, ASPIRANT trial provides the first controlled evidence on the blood pressure-lowering effects of low-dose spironolactone in resistant hypertensive patients.
Authors:
Guido Grassi
Related Documents :
21670255 - Pressure-induced reversible amorphization and an amorphous-amorphous transition in ge...
10414765 - Use of computerized insole sensor system to evaluate the efficacy of a modified ankle-f...
9165395 - The effect of insoles in therapeutic footwear--a finite element approach.
21302725 - Pediatric idiopathic intracranial hypertension: clinical and demographic features.
7306865 - The effect of intravenous diazepam on rise of intraocular pressure following succinylch...
7741295 - The relation between cerebral metabolic rate and ischemic depolarization. a comparison ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-4
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  -     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
University of Milano-Bicocca and Istituto di Ricerca e Cura a Carattere Scientifico Multimedica, Clinica Medica, Sesto San Giovanni , Ospedale S. Gerardo dei Tintori, Via Pergolesi 33, 20052 Monza Milan , Italy +39 039 233 357 ; +39 039 322 274 ; guido.grassi@unimib.it.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bacterial pathogen phytosensing in transgenic tobacco and Arabidopsis plants.
Next Document:  A novel mass spectrometry based method for determining insulin-like growth factor 1: assessment in a...